Sofituzumab vedotin

• CAT Number: I040855
• CAS Number: 1418200-58-4
• Purity: ≥95%

Sofituzumab Vedotin(CAT: I040855) is an antibody-drug conjugate (ADC) designed for targeted cancer therapy. It combines a monoclonal antibody targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) with the cytotoxic agent monomethyl auristatin E (MMAE). The drug selectively binds to TIM-3 expressed on tumor cells, leading to internalization and delivery of MMAE, which inhibits microtubule polymerization and induces cell death. Primarily studied in Cancer Disease Research, Sofituzumab Vedotin is being investigated for its potential in treating various solid tumors, including those with resistance to conventional therapies, by reducing systemic toxicity and improving efficacy.